Policy & Medicine September 8, 2024
Berkeley Research Group (BRG) recently published a study on the relative size of the 340B Program, by comparing it to other federal prescription drug programs and to the overall market for brand outpatient pharmaceuticals in the United States. According to the study, the 340B Program continues to undergo significant growth – largely due to increased program participation, hospital and provider consolidation, and contract pharmacy arrangement expansions.
In 2022, 340B Program sales...
Today's Sponsors
Today's Sponsor